Jianjun Gao

Active 1996–2026

221
Papers
24,685
Citations
63
h-index
156
i10-index

Citations

Citations per year for Jianjun Gao1992: 1 citations1995: 1 citations1997: 4 citations1998: 9 citations1999: 10 citations2000: 7 citations2001: 14 citations2002: 14 citations2003: 15 citations2004: 15 citations2005: 18 citations2006: 20 citations2007: 11 citations2008: 10 citations2009: 16 citations2010: 53 citations2011: 85 citations2012: 98 citations2013: 95 citations2014: 121 citations2015: 133 citations2016: 142 citations2017: 217 citations2018: 247 citations2019: 602 citations2020: 2,286 citations2021: 1,592 citations2022: 1,249 citations2023: 1,048 citations2024: 1,481 citations2025: 901 citations2026: 53 citations2027: 3 citations1993–1994: no citations, so these years are not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,534 citing papers, 22.5% of this breakdownChina: 3,056 citing papers, 19.4% of this breakdownUnited Kingdom: 824 citing papers, 5.2% of this breakdownItaly: 659 citing papers, 4.2% of this breakdownGermany: 636 citing papers, 4.1% of this breakdownFrance: 524 citing papers, 3.3% of this breakdownIndia: 486 citing papers, 3.1% of this breakdownCanada: 458 citing papers, 2.9% of this breakdownAustralia: 390 citing papers, 2.5% of this breakdownJapan: 368 citing papers, 2.3% of this breakdownSpain: 366 citing papers, 2.3% of this breakdownNetherlands: 324 citing papers, 2.1% of this breakdown
0%22.5%Other 26.1%

Fields

  • Medicine58.5%
  • Biochemistry, Genetics and Molecular Biology18.5%
  • Immunology and Microbiology7.5%
  • Computer Science2.8%
  • Engineering2.8%
  • Earth and Planetary Sciences2.4%
  • Other7.5%

Topics

  • Cancer Immunotherapy and Biomarkers9.2%
  • Immunotherapy and Immune Responses3.9%
  • COVID-19 Clinical Research Studies3.5%
  • SARS-CoV-2 and COVID-19 Research3%
  • Immune Cell Function and Interaction2.9%
  • Parkinson's Disease Mechanisms and Treatments2.6%
  • Other74.9%

Coauthors

All papers

Open in search
  1. B cells and tertiary lymphoid structures promote immunotherapy response

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine N. Spencer, Elizabeth M. Burton, Lauren E. Haydu, Alexander J. Lazar, Roberta Zapassodi, Courtney W. Hudgens, Deborah A. Ledesma, SuFey Ong, Michael Bailey, Sarah Warren, Disha Rao, Oscar Krijgsman, Elisa A. Rozeman, Daniel S. Peeper, Christian U. Blank, Ton N. Schumacher, Lisa H. Butterfield, Monika A. Zelazowska, Kevin M. McBride, Raghu Kalluri, James P. Allison, Florent Petitprez, Wolf H. Fridman, Catherine Sautès‐Fridman, Nir Hacohen, Katayoun Rezvani, Padmanee Sharma, Michael T. Tetzlaff, Linghua Wang, Jennifer A. Wargo - Nature 2020 cited by 2,745

  2. The Next Decade of Immune Checkpoint Therapy

    Authors: , , , , , , , - Cancer Discovery 2021 cited by 750

  3. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

    Authors: , , , , , , , , , , , , , , , - Cell 2016 cited by 1,316

  4. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell stem cell 2019 cited by 765

  5. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 721

  6. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , - Nature Medicine 2017 cited by 592

  7. Patient‐Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Junjie Peng, Guoqiang Hua - Advanced Science 2022 cited by 190

  8. Genome-wide association study reveals genetic risk underlying Parkinson's disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katrina Gwinn, Marcel van der Brug, Grisel Lopez, Stephen J. Chanock, Arthur Schatzkin, Yikyung Park, Albert R. Hollenbeck, Jianjun Gao, Xuemei Huang, Nick W Wood, Delia Lorenz, Günther Deuschl, Honglei Chen, Olaf Rieß, John Hardy, Andrew Singleton, Thomas Gasser - Nature Genetics 2009 cited by 1,954

  9. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Padmanee Sharma - Nature Medicine 2020 cited by 313

  10. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jianjun Gao, Linghua Wang - Nature Communications 2021 cited by 224

  11. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 241

  12. Renal cell carcinoma

    Authors: , , - BMJ 2014 cited by 662

  13. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Metabolism 2019 cited by 265

  14. What Is the Significance of Variant Histology in Urothelial Carcinoma?

    Authors: , , , , , , , , , , , - European Urology Focus 2019 cited by 244

  15. LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells

    Authors: , , , , , , , , , , , , , , , , , - Nature Cancer 2024 cited by 62

  16. Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Liuqing Yang - Science Advances 2023 cited by 58

  17. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2023 cited by 58

  18. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vadeerat Rinsurongkawong, J. Jack Lee, Jack A. Roth, Stephen G. Swisher, Ignacio I. Wistuba, John V. Heymach, Jing Wang, Matthew T. Campbell, Eleni Efstathiou, Mark Titus, Christopher J. Logothetis, Thai H. Ho, Jianjun Zhang, Linghua Wang, Jianjun Gao - Nature Communications 2022 cited by 72

  19. Resolving tissue complexity by multimodal spatial omics modeling with MISO

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Methods 2025 cited by 60

  20. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 60

  21. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Virginia Giuliani, Katharina Schlacher, Alessandro Carugo, Timothy P. Heffernan, Padmanee Sharma, José A. Karam, Christopher G. Wood, Cheryl L. Walker, Giannicola Genovese, Nizar M. Tannir - Cancer Cell 2020 cited by 142

  22. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 233

  23. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2019 cited by 151

  24. The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

    Authors: , - Frontiers in Pharmacology 2022 cited by 71